Study on the interaction mechanism between luteoloside and xanthine oxidase by multi‐spectroscopic and molecular docking methods
Journal of Molecular Recognition · 2022-12 · 35 (12)
DOI: 10.1002/jmr.2985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Recognition, online erschienen am 20.08.2022. Verfasst von Junliang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, People's Republic of China. Hauptthemen laut MEDLINE: Xanthine Oxidase, Gout. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Program for Liaoning Innovative Talents in University, Natural Science Foundation of Liaoning Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Gout is an inflammatory joint disease caused by urate crystal deposition, which is associated with hyperuricemia. Gout will take place when the uric acid accumulates. Xanthine oxidase (XO) is a crucial enzyme in the formation of uric acid. Inhibiting XO is one of the means to ameliorate gout. Luteoloside is a kind of natural flavonoid, which has an excellent prospect for relieving gout. But there are few reports on the interaction mechanism between luteoloside and XO currently. In this study, the interaction mechanism between luteoloside and XO was explored using spectroscopy and molecular docking. The fluorescence spectroscopy results indicated that luteoloside could make the intrinsic fluorescence of XO quenched, and the binding constant between luteoloside and XO was (1.85 ± 0.22) × 10 3 L mol −1 at 298 K. The synchronous fluorescence spectroscopy results showed that the absorption peaks of Tyr and Trp shifted blue, and the hydrophobicity of the microenvironment increased. Moreover, CD spectra showed that α‐helix of XO decreased, β‐sheet and β‐turn increased after adding luteoloside. The results of molecular docking analysis showed that XO could combine with luteoloside through hydrogen bonds and hydrophobic force. The results indicated that luteoloside could remarkably interact with XO. Insights into the interaction mechanism provide a necessary basis for the search for low‐toxic natural products as targets of XO. Highlights Luteoloside and xanthine oxidase was a strong binding mode and had only one binding site. Luteoloside could cause α‐helix reduced, β‐sheet and β‐turn increased, and change the secondary structure of XO. The binding between luteoloside and xanthine oxidase was a spontaneous process. The main binding force was hydrophobic force between luteoloside and xanthine oxidase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, People's Republic of China.
- Department of Food Science, College of Light Industry, Liaoning University, Shenyang, People's Republic of China.
ORCID-Profile: Jianli Liu
Förderung
- Program for Liaoning Innovative Talents in University
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Wang, Y., Pan, X., Cheng, Y., Liu, J., & Cao, X. (2022). Study on the interaction mechanism between luteoloside and xanthine oxidase by multi‐spectroscopic and molecular docking methods. Journal of Molecular Recognition, 35(12). https://doi.org/10.1002/jmr.2985
Vancouver
Chen J, Wang Y, Pan X, Cheng Y, Liu J, Cao X. Study on the interaction mechanism between luteoloside and xanthine oxidase by multi‐spectroscopic and molecular docking methods. Journal of Molecular Recognition. 2022;35(12). doi:10.1002/jmr.2985
BibTeX
@article{Chen2022,
author = {Chen, Junliang and Wang, Yuxiao and Pan, Xinyu and Cheng, Ye and Liu, Jianli and Cao, Xiangyu},
title = {Study on the interaction mechanism between luteoloside and xanthine oxidase by multi‐spectroscopic and molecular docking methods},
journal = {Journal of Molecular Recognition},
year = {2022},
volume = {35},
number = {12},
doi = {10.1002/jmr.2985}
}
EUVIMED